With this study, we want to explore the possibility of restoring the susceptibility of multi-drug resistant CRC cells to common, but efficient anti-cancer drugs like doxorubicin, by combination therapy and repositioning of drugs that target the expression of MACC1. The gene discussed is MACC1; the disease is cancer.